Received Dec 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | — | — |
COVID-19 vaccine caused cutaneous mastocytosis, with significant progress after the booster in JUL2021; COVID-19 vaccine caused cutaneous mastocytosis, with significant progress after the booster in JUL2021; This is a spontaneous report received from an Other HCP from medical information team. A patient (age and gender not provided) received BNT162b2 (BNT162B2), in Jul2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1), for covid-19 immunization; Bnt162b2 (DOSE 2, caused cutaneous mastocytosis within 1 week of its administration after the second vaccination back in JAN2021), administration date: Jan2021, for covid-19 immunization, reaction(s): "Mastocytosis". The following information was reported: MASTOCYTOSIS (non-serious), CONDITION AGGRAVATED (non-serious) all with onset 2021, outcome "unknown" and all described as "COVID-19 vaccine caused cutaneous mastocytosis, with significant progress after the booster in JUL2021". Additional information: An HCP told him that the COVID-19 vaccine caused cutaneous mastocytosis within 1 week of its administration after the second vaccination back in JAN2021, with significant progress after the booster in JUL2021. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.